{"id":"W4321436832","doi":"10.1200/jco.22.01989","title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"Chugai Pharmaceutical; EMD Serono; Genentech; Ipsen; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Eisai; Regeneron Pharmaceuticals; Natera; Grifols; Y-mAbs Therapeutics; Shionogi; Actuate Therapeutics; Daiichi Sankyo Europe; Gilead Sciences; Calithera Biosciences; Pfizer; Incyte; Mirati Therapeutics; Les Laboratories Pierre Fabre; Helsinn; Merck KGaA; Sanofi; GlaxoSmithKline; Helsinn Therapeutics; Amgen; Celgene; AstraZeneca; Samsung; Bristol-Myers Squibb","keywords":"Pemetrexed; Medicine; Pembrolizumab; Carboplatin; Internal medicine; Lung cancer; Oncology; Clinical endpoint; Hazard ratio; Phases of clinical research; Clinical trial; Surgery; Cisplatin; Chemotherapy; Cancer; Confidence interval; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008295015,0.0008530571,0.001324665,0.0004420619,0.0004140984,0.0008544055,0.000647559,0.001031001,0.003484302],"category_scores_gemma":[0.003984792,0.0002890856,0.00348438,0.0006298423,0.0004142154,0.001002225,0.0007912453,0.002582471,0.00055457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006871986,"about_ca_system_score_gemma":0.001110867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006413565,"about_ca_topic_score_gemma":0.001746203,"domain_scores_codex":[0.9978807,0.001291457,0.0001679424,0.0001701909,0.0003151816,0.0001744866],"domain_scores_gemma":[0.9975467,0.0006654355,0.0008573222,0.0002506737,0.0001825071,0.0004972911],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8472346,0.01325136,0.0250598,0.002951564,0.01041169,0.0002172429,0.0001795365,0.003588265,0.005523256,0.000692823,0.01763759,0.07325228],"study_design_scores_gemma":[0.5313359,0.2622978,0.1655792,0.000565229,0.01489062,0.0005874027,0.0001633606,0.003582548,0.003097199,0.001271123,0.01651238,0.0001172154],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9527951,0.01385095,0.002519625,0.001431649,0.0003446976,0.003792497,0.01794273,0.0001074466,0.007215346],"genre_scores_gemma":[0.9632807,0.004859684,0.002151913,0.001788721,0.000468965,0.003084478,0.02206558,0.00004325628,0.002256693],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008295015,"threshold_uncertainty_score":0.04386878,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1147099508522471,"score_gpt":0.4737687742129537,"score_spread":0.3590588233607066,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}